Elisabeth Battinelli is a Hematology physician affiliated with Brigham and Women's Hospital. OpenAlex indexes 150 publications with 4,116 citations (h-index 27).
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
1 Blackfan Circle, Karp 5th Floor
Brigham And Women'S Hospital
Boston, MA 021151124
Telephone
617-355-9090Registry record last updated 17 Sept 2014.
Industry payments
2 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- AstraZeneca Pharmaceuticals LPProgram year20251 payment
- SOBI, INCProgram year20241 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2022)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Blood & clotting
100%Factor Xa inhibitor100%Eliquis100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
2 NIH research awards on record, funded 2009–2021 per NIH RePORTER. The latest:
- How does malignancy subvert platelet and megakaryocytic biology?
Brigham and Women'S Hospital
FY2021$550,945R01CA200748 - How does malignancy subvert platelet and megakaryocytic biology?
Brigham and Women'S Hospital
FY2020$550,945R01CA200748 - How does malignancy subvert platelet and megakaryocytic biology?
Brigham and Women'S Hospital
FY2019$534,417R01CA200748
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- International Clinical Practice Guideline Recommendations for Acute Pulmonary Embolism
Journal of the American College of Cardiology
2024 - Platelets and circulating (tumor) cells: partners in promoting metastatic cancer
Current Opinion in Hematology
2024 - Platelet Angiopoietin-1 Protects Against Murine Models of Tumor Metastasis
Arteriosclerosis Thrombosis and Vascular Biology
2024 - False positive lupus anticoagulant tests in patients with high C‐reactive protein: A comparison of two hexagonal phase reagents
International Journal of Laboratory Hematology
2024 - Pro-inflammatory megakaryocyte gene expression in murine models of breast cancer
Science Advances
2022
Similar KOLs
Other experts from the same institution or the same specialty.
Paul Ridker, MD
Brigham and Women's Hospital
Scott Solomon, MD
Brigham and Women's Hospital
Dennis Selkoe, MD
Brigham and Women's Hospital
Marc Pfeffer, MD
Brigham and Women's Hospital
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”